Poisoning: a Study of Nine Cases Occupationally Exposed Due to Inadvertent Spread During Fumigation
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
What's the Best First Line Anticonvulsant?
What’s the best first line anticonvulsant? Stephen Hanson, DVM, MS, Dip. ACVIM (Neurology) Recurring seizure activity is a relatively common problem in canine patients. Nowadays, there are several good options for medical treatment, which makes the choice of which drug to use a little more complicated. All anticonvulsant drugs have advantages and disadvantages, so the selection of a first-line drug should be tailored for the individual patient and client. Phenobarbital: This has been the standard first choice drug for decades. The nice thing about Phenobarbital is that it works fairly well, controlling seizures in about 70% of dogs with epilepsy. Also, it is inexpensive and readily available. The biggest down-sides are its induction of hepatic metabolism and the need for frequent upward dose adjustments, as well as its potential to cause hepatotoxicity. The potential for liver disease increases with time, so a 2 year old dog placed on this medication is more likely to develop hepatotoxicity in his life-time than a 10 year old dog. Phenobarbital can also cause sedation and ataxia. While this is usually mild/transient, it can be a real problem in dogs with other pre- existing signs of intracranial disease. Polyuria, polydipsia and polyphagia are other common side effects. These signs vary widely in severity between patients. Pros: cheap, available at any corner pharmacy, works well Cons: higher doses required with time, possible serious liver side-effects Good first-line choice for middle-aged to older dogs without any pre-existing liver issues Poor choice for dogs with liver disease, dogs with other intracranial signs Questionable choice for young epileptic dogs Potassium/sodium bromide: This was the most commonly-used add on anticonvulsant drug for a long time. -
Management of Status Epilepticus
Published online: 2019-11-21 THIEME Review Article 267 Management of Status Epilepticus Ritesh Lamsal1 Navindra R. Bista1 1Department of Anaesthesiology, Tribhuvan University Teaching Address for correspondence Ritesh Lamsal, MD, DM, Department Hospital, Institute of Medicine, Tribhuvan University, Nepal of Anaesthesiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Tribhuvan University,Kathmandu, Nepal (e-mail: [email protected]). J Neuroanaesthesiol Crit Care 2019;6:267–274 Abstract Status epilepticus (SE) is a life-threatening neurologic condition that requires imme- diate assessment and intervention. Over the past few decades, the duration of seizure Keywords required to define status epilepticus has shortened, reflecting the need to start thera- ► convulsive status py without the slightest delay. The focus of this review is on the management of con- epilepticus vulsive and nonconvulsive status epilepticus in critically ill patients. Initial treatment ► neurocritical care of both forms of status epilepticus includes immediate assessment and stabilization, ► nonconvulsive status and administration of rapidly acting benzodiazepine therapy followed by nonbenzodi- epilepticus azepine antiepileptic drug. Refractory and super-refractory status epilepticus (RSE and ► refractory status SRSE) pose a lot of therapeutic problems, necessitating the administration of contin- epilepticus uous infusion of high doses of anesthetic agents, and carry a high risk of debilitating ► status epilepticus morbidity as well as mortality. ► super-refractory sta- tus epilepticus Introduction occur after 30 minutes of seizure activity. However, this working definition did not indicate the need to immediately Status epilepticus (SE) is a medical and neurologic emergency commence treatment and that permanent neuronal injury that requires immediate evaluation and treatment. It is associat- could occur by the time a clinical diagnosis of SE was made. -
Risk Based Requirements for Medicines Handling
Risk based requirements for medicines handling Including requirements for Schedule 4 Restricted medicines Contents 1. Introduction 2 2. Summary of roles and responsibilities 3 3. Schedule 4 Restricted medicines 4 4. Medicines acquisition 4 5. Storage of medicines, including control of access to storage 4 5.1. Staff access to medicines storage areas 5 5.2. Storage of S4R medicines 5 5.3. Storage of S4R medicines for medical emergencies 6 5.4. Access to storage for S4R and S8 medicines 6 5.5. Pharmacy Department access, including after hours 7 5.6. After-hours access to S8 medicines in the Pharmacy Department 7 5.7. Storage of nitrous oxide 8 5.8. Management of patients’ own medicines 8 6. Distribution of medicines 9 6.1. Distribution outside Pharmacy Department operating hours 10 6.2. Distribution of S4R and S8 medicines 10 7. Administration of medicines to patients 11 7.1. Self-administration of scheduled medicines by patients 11 7.2. Administration of S8 medicines 11 8. Supply of medicines to patients 12 8.1. Supply of scheduled medicines to patients by health professionals other than pharmacists 12 9. Record keeping 13 9.1. General record keeping requirements for S4R medicines 13 9.2. Management of the distribution and archiving of S8 registers 14 9.3. Inventories of S4R medicines 14 9.4. Inventories of S8 medicines 15 10. Destruction and discards of S4R and S8 medicines 15 11. Management of oral liquid S4R and S8 medicines 16 12. Cannabis based products 17 13. Management of opioid pharmacotherapy 18 14. -
Benzodiazepines
Benzodiazepines Using benzodiazepines in Children and Adolescents Overview Benzodiazepines are group of medications used to treat several different conditions. Some examples of these medications include: lorazepam (Ativan®); clonazepam (Rivotril®); alprazolam (Xanax®) and oxazepam (Serax®). Other benzodiazepine medications are available, but are less commonly used in children and adolescents. What are benzodiazepines used for? Benzodiazepines may be used for the following conditions: • anxiety disorders: generalized anxiety disorder; social anxiety disorder; post-traumatic stress disorder (PTSD); panic attacks/disorder; excessive anxiety prior to surgery • sleep disorders: trouble sleeping (insomnia); waking up suddenly with great fear (night terrors); sleepwalking • seizure disorders (epilepsy) • alcohol withdrawal • treatment of periods of extreme slowing or excessive purposeless motor activity (catatonia) Your doctor may be using this medication for another reason. If you are unclear why this medication is being prescribed, please ask your doctor. How do benzodiazepines work? Benzodiazepines works by affecting the activity of the brain chemical (neurotransmitter) called GABA. By enhancing the action of GABA, benzodiazepines have a calming effect on parts of the brain that are too excitable. This in turn helps to manage anxiety, insomnia, and seizure disorders. How well do benzodiazepines work in children and adolescents? When used to treat anxiety disorders, benzodiazepines decrease symptoms such as nervousness, fear, and excessive worrying. Benzodiazepines may also help with the physical symptoms of anxiety, including fast or strong heart beat, trouble breathing, dizziness, shakiness, sweating, and restlessness. Typically, benzodiazepines are prescribed to manage anxiety symptoms that are uncomfortable, frightening or interfere with daily activities for a short period of time before conventional anti-anxiety treatments like cognitive-behavioural therapy or anti-anxiety takes effect. -
Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors
International Journal of Molecular Sciences Article Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors Hana Kubová 1,* , Zde ˇnkaBendová 2,3 , Simona Moravcová 2,3 , Dominika Paˇcesová 2,3, Luisa Rocha 4 and Pavel Mareš 1 1 Institute of Physiology, Academy of Sciences of the Czech Republic, 14220 Prague, Czech Republic; [email protected] 2 Faculty of Science, Charles University, 12800 Prague, Czech Republic; [email protected] (Z.B.); [email protected] (S.M.); [email protected] (D.P.) 3 National Institute of Mental Health, 25067 Klecany, Czech Republic 4 Pharmacobiology Department, Center of Research and Advanced Studies, Mexico City 14330, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +420-2-4106-2565 Received: 31 March 2020; Accepted: 28 April 2020; Published: 30 April 2020 Abstract: Benzodiazepines (BZDs) are widely used in patients of all ages. Unlike adults, neonatal animals treated with BZDs exhibit a variety of behavioral deficits later in life; however, the mechanisms underlying these deficits are poorly understood. This study aims to examine whether administration of clonazepam (CZP; 1 mg/kg/day) in 7–11-day-old rats affects Gama aminobutyric acid (GABA)ergic receptors in both the short and long terms. Using RT-PCR and quantitative autoradiography, we examined the expression of the selected GABAA receptor subunits (α1, α2, α4, γ2, and δ) and the GABAB B2 subunit, and GABAA, benzodiazepine, and GABAB receptor binding 48 h, 1 week, and 2 months after treatment discontinuation. Within one week after CZP cessation, the expression of the α2 subunit was upregulated, whereas that of the δ subunit was downregulated in both the hippocampus and cortex. -
KLONOPIN(R) Tablets (1.0 Mg)
Safety Data Sheet KLONOPIN(R) Tablets (1.0 mg) SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name KLONOPIN(R) Tablets (1.0 mg) Product code SAP-10065806 1.2. Relevant identified uses of the substance or mixture and uses advised against Use - pharmaceutical active substance (anti-epileptic drug) *1 1.3. Details of the supplier of the safety data sheet Company information Enquiries: Local representation: Genentech, Inc. 1 DNA Way South San Francisco USA-CA 94080 United States of America Phone 001-(650) 225-1000 E-Mail [email protected] US Chemtrec phone: (800)-424-9300 1.4. Emergency telephone number Emergency telephone number US Chemtrec phone: (800)-424-9300 *1 referring to: Clonazepam SECTION 2: Hazards identification Classification of the substance or mixture / Label elements GHS Classification no classification and labelling according to GHS Other hazards Note - Benzodiazepines induce central nervous system depression and drowsiness. In addition, longer use may be habit forming. Hence, these compounds are also misused by addicts. *1 *1 referring to: Clonazepam Date: 30.4.15/LS (SEISMO) Replacing edition of: -- Page: 1/8 KLONOPIN(R) Tablets (1.0 mg) SECTION 3: Composition/information on ingredients Characterization mixture of 0.6% Clonazepam with excipients Ingredients Concentration Clonazepam - Combustible dust (No category), USH003 1622-61-3 0.6 % Corn starch 9005-25-8 11.8 % Microcrystalline cellulose 9004-34-6 14.7 % For the full text of the H-phrases mentioned in this Section, see Section 16. SECTION 4: First aid measures 4.1. Description of first aid measures Eye contact - rinse immediately with tap water for 10 minutes - open eyelids forcibly Skin contact - drench affected skin with plenty of water Inhalation - remove the casualty to fresh air - in the event of symptoms get medical treatment 4.2. -
124.210 Schedule IV — Substances Included. 1
1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital). -
Calculating Equivalent Doses of Oral Benzodiazepines
Calculating equivalent doses of oral benzodiazepines Background Benzodiazepines are the most commonly used anxiolytics and hypnotics (1). There are major differences in potency between different benzodiazepines and this difference in potency is important when switching from one benzodiazepine to another (2). Benzodiazepines also differ markedly in the speed in which they are metabolised and eliminated. With repeated daily dosing accumulation occurs and high concentrations can build up in the body (mainly in fatty tissues) (2). The degree of sedation that they induce also varies, making it difficult to determine exact equivalents (3). Answer Advice on benzodiazepine conversion NB: Before using Table 1, read the notes below and the Limitations statement at the end of this document. Switching benzodiazepines may be advantageous for a variety of reasons, e.g. to a drug with a different half-life pre-discontinuation (4) or in the event of non-availability of a specific benzodiazepine. With relatively short-acting benzodiazepines such as alprazolam and lorazepam, it is not possible to achieve a smooth decline in blood and tissue concentrations during benzodiazepine withdrawal. These drugs are eliminated fairly rapidly with the result that concentrations fluctuate with peaks and troughs between each dose. It is necessary to take the tablets several times a day and many people experience a "mini-withdrawal", sometimes a craving, between each dose. For people withdrawing from these potent, short-acting drugs it has been advised that they switch to an equivalent dose of a benzodiazepine with a long half life such as diazepam (5). Diazepam is available as 2mg tablets which can be halved to give 1mg doses. -
Clonazepam) Tablets FDA Approved Labeling Text October 2013
NDA 017533 Klonopin (clonazepam) tablets FDA Approved Labeling Text October 2013 KLONOPIN TABLETS (clonazepam) Rx only DESCRIPTION Klonopin, a benzodiazepine, is available as scored tablets with a K-shaped perforation containing 0.5 mg of clonazepam and unscored tablets with a K-shaped perforation containing 1 mg or 2 mg of clonazepam. Each tablet also contains lactose, magnesium stearate, microcrystalline cellulose and corn starch, with the following colorants: 0.5 mg—FD&C Yellow No. 6 Lake; 1 mg—FD&C Blue No. 1 Lake and FD&C Blue No. 2 Lake. Chemically, clonazepam is 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4 benzodiazepin-2-one. It is a light yellow crystalline powder. It has a molecular weight of 315.72 and the following structural formula: CLINICAL PHARMACOLOGY Pharmacodynamics: The precise mechanism by which clonazepam exerts its antiseizure and antipanic effects is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Convulsions produced in rodents by pentylenetetrazol or, to a lesser extent, electrical stimulation are antagonized, as are convulsions produced by photic stimulation in susceptible baboons. A taming effect in aggressive primates, muscle weakness and hypnosis are also produced. In humans, clonazepam is capable of suppressing the spike and wave discharge in absence seizures (petit mal) and decreasing the frequency, amplitude, duration and spread of discharge in minor motor seizures. Pharmacokinetics: Clonazepam is rapidly and completely absorbed after oral administration. The absolute bioavailability of clonazepam is about 90%. -
Determination of Benzodiazepines in Oral Fluid Using LC/MS/MS
Determination of Benzodiazepines in Oral Fluid Using LC/MS/MS Application Note Forensic Toxicology Authors Introduction Christine Moore, Cynthia Coulter, and Katherine Crompton Benzodiazepines are the most commonly pre- Immunalysis Corporation scribed class of drugs in the USA for the treatment 829 Towne Center Drive of anxiety and insomnia, particularly in the elderly Pomona, CA 91767 [1]. They are also used as muscle relaxants and USA anticonvulsants. They are commonly detected in incidents of driving under the influence of drugs Michael Zumwalt (DUID), often in combination with other medica- Agilent Technologies, Inc. tions [2,3]. Oral fluid is becoming increasingly used 9780 S. Meridian Blvd. as a specimen in many areas of forensic interest, Englewood, CO 80112 including collection at the roadside during traffic USA stops. Its ease of collection, difficulty of adulteration, and applicability to routine testing Abstract has promoted its use as a valid test specimen. However, the detection of benzodiazepines in particular in oral fluid is not without difficulty A rapid, simple, highly sensitive procedure for the simul- since the saliva:plasma ratio for most of the drug taneous analysis of 14 benzodiazepines in oral fluid, using class is low. the Agilent 6410 Triple Quadrupole Mass Spectrometer (QQQ) in electrospray mode, is described. Sample prepa- One of the main issues with the quantitation of ration includes solid-phase extraction, evaporation of the drugs in oral fluid is the difficulty of collection in final eluent to dryness, and reconstitution in mobile phase terms of specimen volume. Many of the currently for injection into the LC/MS/MS system. -
Management of Acute Seizure and Status Epilepticus
Management of acute seizure and status epilepticus Apisit Boongird, MD Division of Neurology Ramathibodi hospital Outlines • Seizure cluster/ Acute repetitive seizures • Status epilepticus Seizure cluster • A 45-yo male with past medical history of brain tumor s/p partial tumor removal presented to the outpatient clinic with chief complaint of frequent and repetitive focal seizures with preserved awareness for a day. Each seizure was characterized by left face clonic with preserved awareness, lasting for two hours. He had experienced seizure clusters, 4 times a day. He had one GTCs. Definition of epileptic seizure by the International League Against Epilepsy (ILAE) • An epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Epilepsia, 46(4):470–472, 2005 Acute Repetitive Seizures (ARS) • The practical definition of acute repetitive seizures has not been established. • Acute repetitive seizures is neurologic emergency and a common clinical phenomenon describing an increase in seizures occurring over a specific period of time (ranging from several minutes up to 24 hours). • Acute repetitive seizures may include any type of seizure and may vary in severity, but by definition there is complete recovery in between seizures. Curr Opin Neurol 2015;28(2):143Y150. Oral tablet benzodiazepine • Lorazepam • Clonazepam • Clobazam Outpatient acute benzodiazepine therapy • Rectal diazepam is the only currently marketed treatment available for use by nonmedical caregivers in the USA, and buccal midazolam is approved in the European Union. Outpatient acute benzodiazepine therapy Medications Formulation Notes Diazepam oral tablet rectal gel N Engl J Med 1998; 338:1869–1875. -
186.Full.Pdf
186 CHEMISTR Y: BA NCROFT AND R UTZLER. JR. PROC. N. A. S. I This work is part of the programme now being carried out at Cornell University under a grant from the Heckscher Foundation for the Advancement of Research estab- lished by August Heckscher at Cornell University. 2 Holleman, Rec. trav. chim., 24, 140 (1905). 3 Holleman, Ibid., 23, 225 (1904). 4Drogin and Rosanoff, J. Am. Chem. Soc., 38, 711 (1916). 5 Kraay, Rec. trav. chim., 48, 1055 (1929). 6 De Grauw, Ibid., 48, 1061 (1929). RE VERSIBLE COAGULA TION IN LIVING TISSUE. II By WILDER D. BANCROFTr AND J. E. RUTZLER, JR.2 BAKER CHEMICAL LABORATORY, CORNELL UNIVERSITY Communicated March 3, 1931 Since relief from the addiction to drugs is one of the important problems of the civilized world, it seems wise to see what the outcome is from the application of Claude Bernard's theory of anesthesia to morphinism. Gwathmey' says: "The ganglion cell, according to Binz, is the point of attack of the anesthetic agent. In his experiments, fresh sections of the brain cortex of rabbits were placed in a one per cent solution of morphine hydrochloride, or exposed to chlorine vapors. The effect of coagulation- necrosis was produced, as is seen when protoplasmic poisons of neutral reaction are allowed to act upon large transparent infusoria. The proto- plasm is first darkened, and the movements become sluggish; later the protoplasm becomes granulated, and the movements cease. Recupera- tion may take place from the first stage by washing away the poisons [it can be seen that this is the same as the peptization of gels by washing out the coagulating agent]; but not from the last stage.